Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of …
F Bea, E Blessing, MI Shelley, JM Shultz… - Atherosclerosis, 2003 - Elsevier
Recent studies suggest that the beneficial effects of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG CoA) reductase inhibitors (statins) in reducing cardiovascular events may in part, be
independent of their capacity to lower plasma lipids. To test this hypothesis, simvastatin (50
mg/kg/d) was administered to 30-week-old apolipoprotein E deficient mice (apo E−/−) for 12,
18 and 24 weeks. In contrast to other experimental models and humans, simvastatin
treatment increases plasma cholesterol levels in apo E−/− mice. Quantitative real-time …
(HMG CoA) reductase inhibitors (statins) in reducing cardiovascular events may in part, be
independent of their capacity to lower plasma lipids. To test this hypothesis, simvastatin (50
mg/kg/d) was administered to 30-week-old apolipoprotein E deficient mice (apo E−/−) for 12,
18 and 24 weeks. In contrast to other experimental models and humans, simvastatin
treatment increases plasma cholesterol levels in apo E−/− mice. Quantitative real-time …